A Agilent Technologies Inc.

Agilent Named One of the Best U.S. Companies for Diversity for Third Straight Year

Agilent Technologies (NYSE: A) today was named one of the top U.S. companies for diversity, marking the third straight year it has been recognized for its commitment to fostering a diverse and inclusive workplace.

This press release features multimedia. View the full release here:

Specifically, Agilent ranked No. 83 out of 500 companies on Forbes’s 2021 of America’s Best Employers for Diversity.

The rating was based on dimensions of diversity including gender, ethnicity, LGBTQ+, age, and the differently abled.

Agilent CEO Mike McMullen said he was proud of the recognition – not only because Agilent was ranked in the top 100, but also because the achievement relates to diversity, an essential component of Agilent’s values.

“We are committed to infusing diversity and inclusion into every aspect of how Agilent does business,” McMullen said. “While there is always room for improvement, we’re excited that our good work thus far is being recognized inside and outside the company.”

Forbes based its rankings on an anonymous survey of more than 50,000 U.S. employees at companies that have at least 1,000 U.S.-based employees. Agilent was not involved in any aspect of the survey.

Agilent’s top-100 ranking is a rewarding indication of how well its efforts are being received by employees, said Dominique Grau, Agilent’s vice president of human resources.

“We strive to foster a workplace where all employees can feel comfortable being their true selves,” Grau said. “I’m thrilled by what our ranking says about how aligned our employees are with the journey we are taking.”

Agilent has implemented several initiatives to strengthen diversity and inclusion – especially within the last year.

For example, in the wake of national social unrest in 2020, McMullen held listening sessions with Black employees and helped establish a networking group for Black employees in the U.S.

The company also sponsored events including a Women in Engineering forum in Silicon Valley and a mentorship program for Indigenous students in Australia.

Last year, Agilent also hired Patrice Jimerson, a diversity practitioner with 25 years of experience, to lead its diversity and inclusion program.

“Our people are our strength, and we are strongest when we all contribute our unique and individual perspectives,” Jimerson said. “Agilent is committed to investing the resources we need to do an even better job. I am excited to lead that journey.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets, delivering insight and innovation toward improving the quality of life. Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at . To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on , , and .

EN
20/04/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Agilent Technologies Inc.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approva...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ , a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise and reliable cell analysis solutions, Agilent assisted Autolus in achieving the high standards required for FDA approval. Dr. Xiaobo Wang, Vice President and General Manager of the Cell Functio...

 PRESS RELEASE

CORRECTING and REPLACING Agilent to Showcase Next-Generation Digital P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 (NYSE: A) is excited to announce its participation at the upcoming , which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology, Agilent offers comprehensive tissue diagnostic solutions for analyzi...

 PRESS RELEASE

Agilent Research Catalyst Award Presented to Columbia University for P...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced that has received an Agilent Research Catalyst (ARC) Award on behalf of , an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunotherapy Laboratory at Columbia University Irving Medical Center. He is also an Assistant Professor of Medicine at Columbia University Medical Center, a principal investigator at the Columbia Center for Translational Immunology (CCTI), and a member of the Herbert Irv...

 PRESS RELEASE

Agilent PD-L1 IHC 28-8 pharmDx Receives EU IVDR Certification as a Com...

SANTA CLARA, Calif.--(BUSINESS WIRE)-- (NYSE: A) today announced its kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications launched in Europe for PD-L1 IHC 28-8 pharmDx to nine. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the advanced staining solution. Lung cancer and malignant melanoma are major healthcare concerns worldwide, with lung cancer accountin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch